Antifungal gel pharmaceutical composition and method for its preparing
FIELD: medicine, dermatology, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to an antifungal gel pharmaceutical composition based on ketoconazole and clotrimazole that are derivatives of imidazole. The composition comprises ketoconazole or clotrimazole as an active component, polyethylene glycol-400 (PEG-400) as a solvent, carboxyvinyl polymer as a gel-forming agent, polyethylene glycol as a gel stabilizing agent, organic amine or inorganic bas as a regulator of pH and water taken in the definite ratio of components. The composition is prepared by dissolving active component in PEG-400, dispersing carboxyvinyl polymer in water, successive addition to dispersion propylene glycol as a stabilizing agent and regulator of pH and combination of prepared solution and gel followed by stirring the mixture up to preparing the gel composition with pH 5-7. Invention provides preparing antifungal composition with reduced adverse effect.
EFFECT: improved preparing method, valuable medicinal properties of composition.
2 cl, 1 tbl, 11 ex
The invention relates to chemical-pharmaceutical industry and medicine, namely to antifungal gel pharmaceutical compositions based on derivatives of imidazole - ketoconazole and clotrimazole.
Clotrimazole (canesten) and ketoconazole (nizoral) has gotten the most publicity and the distribution of the entire group of imidazole antimycotics. Clotrimazole, or bis-phenyl-(2-chlorophenyl)-1-imidazolidin with the gross formula C22H17Cl2and molecular mass (MM) 344,8, was synthesized in 1967, the German company Bayer. The mechanism of action clotrimazole is the inhibition of the synthesis of nucleic acids, lipids and polysaccharides in the cells of the pathogenic fungus that causes damage to cell membranes, its dissolution, the increased permeability of phospholipid membranes of lysosomes [Cheglakov N, Rukavishnikov V. Imidazole drugs in Mycology//journal of dermatology and venereology. - 1984. No. 6. - P.51-57]. Clotrimazole has a broad antifungal spectrum. The drug is active against pathogenic dermatophytes, yeast fungi, pathogens multi-colored lichen, amitraz, some gram-positive (Staphylococcus, Streptococcus) and gram-negative bacteria, Trichomonas vaginalis. Dignity drugs clotrimazole is its good penetrating ability with the skin surface of the stratum corneum is the layer of the epidermis. Also, the positive side is the ability to clotrimazole to accumulate in the deeper layers of the epidermis, where its concentration can reach values above the minimum overwhelming concentration (MBC) for dermatophytes. When applying the product on the nail, clotrimazole can penetrate the layers of keratin [Register of medicines of Russia. Encyclopedia of drugs. Ed. 10-E. M., 2003].
Ketoconazole is a new drug of the group of imidazoles. Unlike clotrimazole drugs ketoconazole effectively applied not only locally, but also oral. An important feature of ketoconazole is its effect on superficial and systemic mycoses. This makes possible its use in the treatment of fungal infections [Mashkovsky PPM Medicines: a Guide to pharmacotherapy for physicians: 2 hours Part 1, s, M, LLC "New wave", 2002]. Ketoconazole or CIS-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(NH-imidazol-1-ylmethyl)-1,3-dioxolane-4-yl]methoxy]phenyl]-piperazine was synthesized in 1978 by the Belgian company “Jansen” in the form of water-soluble drug R-41400. Its formula is C26H28About4N4Cl2[Potekaev NS, Sosnin E.A. Nizoral. Perspectives of use and side effects//journal of dermatology and venereology. - 1987, No. 8, p.20-25]. Drugs ketoconazole is effective in the treatment of dermatomycosis, onychomycosis, mikoto the hair of the head, vaginal mycosis [Register of medicines of Russia. Encyclopedia of drugs. ISD-E. M., 2003, s]. Currently on sale there are many drugs clotrimazole and ketoconazole for topical application in the form of ointments, creams and solutions. The most widely manufactured by Pharma drugs in the form of alcoholic solutions and ointments. The disadvantage of liquid forms are the high turnover of the drug and the volatility of the solvent, resulting in the active component is not sufficiently fixed on the skin surface and does not penetrate inside, remaining on the surface in the form of a friable powder. Known [RF patent 2120305, IPC And 61 To 47/38, 1998] farmcampsite in the form of a cream containing clotrimazole or ketoconazole, the derived methyl cellulose, castor oil, preservative, stabilizer and additives target. The disadvantage of the composition is that the active substance is not dissolved, but in the form of dispersion, so not penetrate from the surface of the skin in its deep layers, which decreases therapeutic effect of the composition. In addition, castor oil is irritating effect on the mucous membranes, which limits the scope of application of the drug, for example, in the treatment of vaginal mycoses.
Known [U.S. patent 4267169, IPC And 61 To 31/74, 31/415, 1981] the pharmaceutical composition in the form of a gel, comprising clotrimazol is as an active ingredient. The composition contains as solvent crotamiton mixed with ethyl alcohol, carboxyvinyl polymer as a gelling agent, a pH regulator, an organic amine and propylene glycol as the water-bonding component. The disadvantage of the composition is the fact that one of its components - crotamiton has a side effect - causes severe skin irritation, is not suitable for children (under 12 years) [Register of medicines of Russia. Encyclopedia of drugs. ISD-E. M., 2003, p.472-473].
Closest to the claimed invention, the essential features is the composition in the form of a gel [patent EP 0186055, IPC a 61 K 31/415, 1986]. This composition contains (wt.%): as the active substance is clotrimazole or bifonazole - 0.5-3; as a gelling agent carboxyvinyl polymer is 0.1-3; as solvent - 1,3-butyleneglycol - 5-90 and, preferably, additional ethanol - 30; as the pH regulator is an organic amine and water. The disadvantage of gel on Pat. EP 0186055 is the presence of 1,3-butyleneglycol with irritant effect on skin and mucous membranes, which is an undesirable side effect of the drug [Harmful substances in industry. A Handbook for chemists, engineers and doctors. ISD-that is, Volume 1. Organic substances. Under re is. Professor Nuvasive, MD Anglewing. L., "Chemistry", 1976, s]. In addition, the gel typically contains ethanol, which, in turn, has tanning and irritant effect on skin and mucous membranes [Register of medicines of Russia. Encyclopedia of drugs. ISD-E. M., 2003, s]. Tanning action of ethyl alcohol leads to strengthening and thickening of the walls of the spores of the fungus, and thereby reduces therapeutic effect of the drug.
The task of the invention is to develop a gel pharmaceutical compositions on the basis of ketoconazole or clotrimazole with reduced side effects.
The problem is solved in that the antifungal gel pharmaceutical composition comprising the active ingredient is a derivative of imidazole, organic solvent, carboxyvinyl polymer as a gelling agent, a pH regulator and water, contains as the organic solvent is a glycol-400 (PEG-400), and as derived imidazole contains a substance selected from the group including ketoconazole and clotrimazole and additionally contains propylene glycol (PG) as a stabilizer of the gel in the following ratio of components (wt.%):
Clotrimazole or ketoconazole 0.5-3.0
The polyethylene glycol 400 15.0-70.0
Propylene glycol 1.0-70.0
Carboxyvinyl polymer .5-3 .0
The pH regulator 0.05-3.0
Water the rest
The inventive composition provides reduced side irritants through the use of an inert solvent is PEG-400, PEG-400 in combination with PG provides excellent consumer properties, namely: the application of the drug is aesthetic in appearance, does not spread through the use of stabilizing additives, does not stain clothing, easily removed and washed.
The authors first used in the gel composition ketoconazole. The composition has excellent therapeutic effect.
Gel composition according to patent EP 0186055 obtained by mixing the active component - clotrimazole or bifonazole with an organic solvent, heated to 65-75°, 1,3-butyleneglycol and ethyl alcohol, a gelling agent, an organic amine and water. The disadvantage of this method is the use of 1,3-butyleneglycol, which has a relatively low flash point (121°C), is very hygroscopic, under normal conditions, is easily oxidized in the air, which require special conditions of storage and handling. 1,3-butyleneglycol has no status pharmacopoeial product.
The present invention is to develop a simple, safe, technologically advanced way to obtain gel.
The problem is solved in that in the method of obtaining PR is telegraphos gel farbkomposition, including mixing the active component - imidazole derivative with an organic solvent, a gelling agent carboxyvinyl polymer, a pH regulator and water, as an active ingredient use ketoconazole or clotrimazole, the solvent is PEG-400 and impose additional stabilizer gel - PG, and the active ingredient is dissolved in PEG-400 when heated, carboxyvinyl polymer is dispersed in water, the dispersion is sequentially mixed with PG and pH regulator, and the resulting mass is combined with a solution of the active component under stirring to obtain a gel with a pH of 5-7.
The advantage of the proposed method is that it provides a simple and safe process for the production of the gel due to the use of PEG-400 as solvent, does not require special conditions of production and can be performed on conventional manufacturing equipment for the production of soft medicinal forms. PEG with molecular weight of 400 is inert, non-toxic solvent, recommended for use in the pharmaceutical industry. In a production environment toxic effect of PEG-400 was not detected [Harmful substances in industry. A Handbook for chemists, engineers and doctors. ISD-that is, Volume 1. Organic substances. Edited by Prof. NFL is AREVA, MD Anglewing. L., "Chemistry", 1976, s]. PEG-400 has the status of a pharmaceutical product [FS 42-1242-96] and is widely used as excipients for the production of many medicines, including soft medicinal forms.
The inventive composition and method of reception ensure the creation of new antifungal gel drug with excellent medicinal properties, with reduced side effects, as well as simple and safe production technology.
For the production of the inventive anti-fungal gel pharmaceutical composition can be used with a wide range of redkostej carboxyvinyl polymers based on acrylic acid. During the development of the claimed composition, we used carboxyvinyl polymers grades of Carbopol 974P NF and Carbopol 934P NF Belgian company BF Goodrich.
As the pH regulator may be used organic amines or inorganic bases. As organic amines can be used mono-, di - or trialkanolamines, mono-, di - or trialkylamine; as inorganic bases can be used sodium hydroxide or potassium. During the development of the claimed composition we used diethylamine (deja) THE 6-09-68-89, triethanolamine (tea) THE 6-09-982-96 and NaOH in the form of a 10% solution.
During the development of the claimed composition and the pic is her BA get used substance of clotrimazole ND 42-9851-99 Chinese manufacturer "tai yuan pharmaceutical, Factory and substance ketoconazole ND 42-10696-00 Indian firms "global Balk " & Fayne chemicals LTD.". In the manufacture of the claimed antifungal gel pharmaceutical composition can be used all registered in the Russian Federation substance of ketoconazole and clotrimazole. Were also used GHG VFS 42-1594-86 and PEG-400 FS 42-1242-96.
The invention is illustrated by the following examples.
The substance of clotrimazole (1 g) is mixed with PEG-400 (15 g), heated to 65-75°C and stirred until complete dissolution of clotrimazole, cooled to room temperature. The carbopol R NF (1 g) was dispersed in water (19 g) before the formation of mass without lumps. In the resulting mass is injected GHG (63.6 g) and tea (0.4 g) and stirred until homogeneous, transparent gel. In the resulting mass is injected solution clotrimazole in PEG-400. Mix until a homogeneous mass. Got a gel with a pH 6.09.
Composition was prepared as described in example 1. The composition and properties of the resulting gels are shown in table 1.
The authors found the optimal values of the concentration of PEG-400, providing the necessary level of solubility of clotrimazole and ketoconazole, and hence the level of specific activity of the drug. The claimed values carboxy-vinyl polymer provide an effective release of the active substance.
Study of biological activity of C which show the means were compared with standard samples clotrimazole and ketoconazole dissolved in an inert carrier - PEG-400. Was used trehgogny method of diffusion in agar (hole modification of Petri-dish) [State Pharmacopoeia of the USSR, XI edition, issue 2, M, "Medicine", 1990, s-225]. As the test cultures were selected Candida albicans and Staphylococcus aureus. Petri dishes after drug application and standard solutions were cultivated under standard conditions (Candida albicans - 24 hours at T=24°; Staphylococcus aureus - 4 hours at 26°). After the time of cultivation were obtained a clear zone of growth inhibition of the test organisms. The most pronounced effect of the drugs possessed against Candida albicans (with a standard load of microorganism), and to a lesser extent against Staphylococcus aureus. In all cases, the diameter of the zones of growth inhibition of the test cultures when making preparations were comparable to zones when making standard samples relatives concentrations, and in some cases exceeded them. This suggests that the release of the active substance in vitro of drug is equal or greater extent in comparison with an inert carrier.
The proposed tool has been tested in vivo in acute, subacute and chronic toxicity and local irritation. The experiments were performed on white nonlinear mice and rats. It is shown that in conditions of long-term (30 days of continuous use (application on an exposed surface) the composition does not cause violations of biochemical parameters of blood, no adverse effects on internal organs, does not cause local irritation.
The components of the composition are widespread industrial products, method of its manufacture is simple and safe and can be performed on standard equipment.
Variants of the claimed composition and its properties.
|Examples||The composition, wt.%||Properties of composition|
|Clotrimazole||Ketoconazole||PEG-400||Propylene glycol||Gelling agent||The pH regulator||Water||pH||Description|
|The carbopol R NF||The carbopol R NF||The tea||Deja||10% NaOH aq|
|8.||2,00||67,00||10,00||1,00||-||0,08||-||-||19,92||6,22||Colorless, transparent gel when stored Pets pink coloration.|
|10.||-||3,00||67,00||10,00||1,00||-||0,08||-||-||18,92||6,36||Colorless, transparent gel when stored Pets pink coloration.|
|11.||1,00||-||70,00||1,00||1,00||-||0,40||-||-||26,60||6,40||Colorless, transparent gel|
1. Antifungal gel pharmaceutical composition comprising the active substance is a derivative of imidazole, organic solvent, carboxyvinyl polymer as a gelling agent, a pH regulator and water, characterized in that it contains as a solvent of the glycol, and as active substances it contains a substance selected from the group comprising ketoconazole or clotrimazole and additionally contains propylene glycol as a stabilizer of the gel in the following ratios, wt.%:
Ketoconazole or clotrimazole 0.5-3.0
The glycol 15.0-70.0
Propylene glycol 1.0-70.0
Carboxyvinyl polymer is 0.5 to 3.0
The pH regulator 0.05-3.0
Water the Rest
2. The method of obtaining antifungal gel pharmaceutical composition according to claim 1, comprising mixing the active ingredient with a gelling agent carboxyvinyl polymer, organic solvent, pH regulator and water, characterized in that the solvent used PEG-400, propylene glycol - as a stabilizing additive, the active ingredient is dissolved in PEG-400 when heated, carboxyvinyl polymer is dispersed in water, the dispersion is consistently mesilat with propylene glycol and pH regulator, the obtained gel is combined with a solution of the active ingredient and mix until a homogeneous gel composition with a pH from 5 to 7.
FIELD: medicine, veterinary science, mycology.
SUBSTANCE: the suggested preparation for external application includes the mixture of Microsporum canis, Microsporum gypseum and Trichophyton mentagrophytes homogenates at the ratio of 1:1:2 in solvent, for example, in physiological solution, and formalin. Concentration of mycotic elements corresponds to 50.0-500.0 mln./ml ready-to-use product. This preparation should be applied in the method to treat dermatomycosis due to rubbing it into affected skin sites till hyperemia at 0.2-2.0 ml preparation/1-4 sq.cm skin surface once daily for 4-6 d. Both the preparation and the method suggested provide healing during the terms mentioned being convenient, reliable and efficient.
EFFECT: higher efficiency of therapy.
4 cl, 5 ex
FIELD: chemico-pharmaceutical industry.
SUBSTANCE: the present innovation deals with new stabilized pharmaceutical composition in its lyophilized form including the compound of formula I
as an active ingredient and lactose disaccharide as a stabilizing agent. The present pharmaceutical compositions are of high stability at storage. As for active ingredient it is not destroyed in the course of time.
EFFECT: higher efficiency.
10 cl, 15 ex, 6 tbl
SUBSTANCE: preparation comprises echinocandine substance of formula I or its pharmaceutically permissible salt, pharmaceutically permissible micelle-forming surface-active agent and non-toxic aqueous solvent and stabilizing agent.
EFFECT: improved stability and bioaccessibility properties.
48 cl, 4 tbl
FIELD: medicine, dermatology, pharmacy.
SUBSTANCE: invention relates to an antifungal preparation for external applying. The preparation comprises 2-chloro-4-nitrophenol, polyethylene glycol (PEG-400) and 50% ethyl alcohol. The preparation is used for treatment of epidermophytosis, trichophytosis, fungal eczema, cutaneous candidiasis and other diseases. Invention provides preparing the more effective antifungal preparation based on the domestic raw.
EFFECT: enhanced effectiveness of preparation, valuable medicinal properties.
FIELD: medicine, cosmetics.
SUBSTANCE: the present innovation deals with, a) at least, one fungicide substance and b) at least, one water-soluble film-forming substance, where b)-component is chitosan derivative chosen out of hydroxyalkyl chitosans and carboxyalkyl chitosans; nail vanish that includes the above-mentioned composition, and nail vanish that includes, at least, one water-soluble film-forming substance chosen out of hydroxyalkyl chitosans and carboxyalkyl chitosans. The suggested nail vanish is of high fungicide action and is free of multiple dermatological and esthetic disadvantages.
EFFECT: higher efficiency of application.
23 cl, 10 ex, 1 tbl
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to curative ointments with anti-inflammatory effect and with biostimulating properties for treatment of burns, suppurative and infected wounds of different etiology and to a method for treatment above said diseases using the ointment said. The proposed ointment comprising bee wax and greasy basis comprises colophony additionally. As greasy basis the ointment comprises butter and vegetable oil in the following ratio of components, wt.-%: bee wax, 20-30; butter, 30-40; vegetable oil, 15-25; colophony, 15-25. Method involves applying ointment by thin layer 0.5-3 mm on dense cotton fabric, its applying to damaged site, keeping and removing ointment with change of bandage 1-3 times per 24 h for 3-14 days. Method provides enhancing the therapeutic effectiveness of ointment due to significant acceleration the healing process of suppurative wounds and insidious furuncles being the ointment doesn't cause irritating effect.
EFFECT: improved and valuable medicinal properties of ointment.
2 cl, 4 ex
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to medicinal preparations used for treatment of suppurative wounds. Invention involves applying boric acid (powder) and multi-component ointments on water-soluble base (Laevomecolum or Laevosinum) taken in the ratio 1:10 and used for treatment of suppurative wounds. Invention provides the development of agent exhibiting the expressed antibacterial, dehydrating and necrolytic effect.
EFFECT: valuable medicinal properties of agent.
FIELD: medicine, in particular homoeopathic ointment for treatment of hemorrhoids, dermatitis and rhinitis.
SUBSTANCE: claimed ointment includes Calendula D 1, Hamamelis D 1, Aesculus D 1, and menthol as active ingredients and zinc oxide and vaseline as ointment base in specific ratio. Ointment of present invention makes it possible to improve microcirculation and cell respiration in tissues, to reduce venous engorgement, to increase immunity, to stimulate regeneration processes.
EFFECT: ointment for treatment of hemorrhoids, dermatitis and rhinitis of improved effect.
SUBSTANCE: the present innovation deals with preparing ointments to be applied at treating both surface and deeply penetrating cutaneous burns and other skin diseases, as well. Composition of the suggested ointment includes, weight%: 45…67% food sunflower oil, 15…37% food olive oil, 1…2% Calendulae officinalis extract, 0.8…1.8% labdanum, 2.5…8% colophony, 6.5…11.5% white bee wax, 0.7…1.8% the main bismuth gallate and 0.7…1.8% camphor. The suggested ointment is highly efficient for rapid and successful treatment of burns III and IV degree. It should be also applied for treating shin's ulcer and, also, in gynecology - for treating inflammation of uterine cervix.
EFFECT: higher efficiency of therapy.
SUBSTANCE: the present innovation deals with cryoprotective ointment containing recombinant interferon-α2. The suggested cryoprotective ointment contains recombinant interferon-α2, glycerol, polyethylene glycol 300-6000, polyglucin, buffered 0.02%-Trilon B solution at pH of 5.5-7.0 and ointment foundation at a certain content of components per 1.0 g ointment. Additionally, cryoprotective ointment could contain glycine 3,7-bis(dimethylamino)phenothiazonium chloride, dry immunoglobulin preparation or dry immunoglobulin preparation for enteral application. Ointment foundation of cryoprotective ointment could contain water-free lanolin, Vaseline and Vaseline oil, at the following ratio of components: 2.5;3.5:1 - 6.5:0.5:1. The innovation provides maximal safety of recombinant interferon-α2 activity in cryoprotective ointment at multiple alteration of positive and negative environmental temperature and at keeping cryoprotective ointment under these conditions.
EFFECT: higher efficiency of application.
8 cl, 8 ex
SUBSTANCE: the suggested composition has got viscosity being below of about 15000 cP and pH being approximately 3.0-9.0 for treating human skin diseases. He suggested composition consists of (a) therapeutically efficient quantity of, at least, one compound being useful in treating the above-mentioned disease; (b) pharmaceutically acceptable, partially bound polymer of polyacrylic acid being compatible with the compound; (c) not obligatory, a solvent being mixed with water, (d) not obligatory, a conserving agent, (e) not obligatory, a component of butyric phase and acceptable surface-active substance, and (f) water. The suggested composition is useful to treat inflammatory skin disease, acne or acne erythematosa. The composition of low viscosity has got its advantage in the fact that it is applied more accurately when in contact with a container that doses the composition in the form of drops.
EFFECT: higher efficiency of application.
23 cl, 15 ex, 19 tbl
FIELD: medicine, gynecology, pharmacology, pharmaceutical industry.
SUBSTANCE: invention proposes a preparation that comprises bacterial mass of live microorganisms as an active component, protecting medium and fat base. The preparation comprises lactobacilli as bacterial mass and one or some eubiotic microorganisms taken among the following group: bifidobacteria, streptococci and lactococci taken in the amount per a single dose. Also, the preparation comprises additionally an acceptable sorbent and a biologically active supplement. Also, invention relates to a method for preparing this preparation that involves preparing firstly lactobacilli bacterial mass and one or some genus of eubiotic microorganisms taken among the following group: bifidobacteria, streptococci and lactococci. Then the prepared bacterial mass of microorganisms is immobilized on sorbent used in medicine in its ratio to bacterial mass of microorganisms = (9-1):(1-9) followed by addition of the protecting medium and biologically active supplement to formed mass in the necessary amount. Also, invention describes a method for prophylaxis and treatment of bacterial vaginitis that involves intravaginal administration of the preparation described above in the amount 1-3 doses, 1-3 times per 24 h. The treatment course is prescribed individually. Invention provides expanding assortment of agents used for treatment of bacterial vaginitis. Invention can be used in obstetric-gynecological practice.
EFFECT: improved method for vaginitis treatment, valuable medicinal properties of preparation.
13 cl, 4 tbl, 1 ex
SUBSTANCE: the present innovation deals with medicinal preparation as an ointment for treating skin burns. The suggested preparation contains bee wax, propolis and vegetable oil. Thus, application of initially intact propolis and bee wax in combination with fatty foundation as vegetable oil enables to cheapen and simplify the technique to prepare the preparation, and optimally matched consistence provides prolonged safety of the preparation and accelerates healing of skin burns.
EFFECT: higher efficiency of therapy.
1 cl, 2 ex
FIELD: organic synthesis.
SUBSTANCE: invention provides a method for preparing water/glycerol complex of (2,3-dihydroxypropyl) ortho-titanate hydrochloride (chloride) having symbolic name "Ephtiderm", which is depicted by following empirical formula: Method consists in that glycerol is mixed with butyl ortho-titanate at molar ratio 12:1, whereupon butanol is distilled off in vacuum, residue is treated with water and aqueous hydrochloric acid to form reaction mass with pH 2.2-3.0, which is heated in vacuum. Method is characterized by that glycerol is mixed with low-grade butyl ortho-titanate and chloroform, reaction mass during the synthesis is maintained at temperature up to 100°C in vacuum 40-200 mm Hg, while chloroform is added at 40-50°C in amount corresponding to 1 L chloroform per 2 L low-grade butyl ortho-titanate.
EFFECT: reduced expenses due to use of low-grade butyl ortho-titanate and simplified technology.
1 tbl, 3 ex
FIELD: pharmaceutical industry.
SUBSTANCE: invention provides novel nontoxic and highly bioavailable acyzol-based agent characterized by high activity in treatment of skin diseases, in restoration of structural skin processes, suppression of nevus pigmentosis, and flattening of folds.
EFFECT: increased assortment of skin-healing drugs.
7 cl, 4 ex
FIELD: medicine, gynecology, anesthesiology.
SUBSTANCE: invention concerns to a method for carrying out the anesthesiology assistance for woman in childbirth with accompanying bronchial asthma. Method involves administration of atropine, dimedrol, analgin and clophelin. Method involves additional intravenous administration of transamine for 5-7 min. Transamine is administrated in doses 12-14 and 15-17 mg/kg in woman in childbirth with body mass 75 kg and above and 74 kg and less, respectively. Method provides enhancing quality and safety of anesthesia in this class of woman in childbirth.
EFFECT: improved assistance method.
7 tbl, 4 ex